Search
Prothrombin
go.drugbank.com/drugs/DB11311ApprovedInvestigationalProthrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.
Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETNOX-100
go.drugbank.com/drugs/DB05799InvestigationalNOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock. … NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body.
Growth/differentiation factor 15
go.drugbank.com/bio_entities/BE0010537TargetHumansHormone produced in response to various stresses to confer information about those stresses to the brain, and trigger an aversive response, characterized by nausea, vomiting, and/or loss of appetite (PubMed:23468844, PubMed:24971956, Pub...
Polypeptides: Growth/differentiation factor 15Synonyms: GDF-15Resorcinol
go.drugbank.com/drugs/DB11085ApprovedInvestigationalIt is used as an antiseptic and disinfectant in topical pharmaceutical products in the treatment of skin disorders and infections such as acne, seborrheic dermatitis, eczema, psoriasis, corns, calluses … Although it is primarily indicated for use as a topical application, resorcinol also possesses a well-documented anti-thyroidal activity that is generally not relied upon for any kind of formal therapeutic
Synonyms: m-Hydroquinone, m-hydroxyphenolMixtures: BUCO-BLEU KOLLUTUVAR, 15 ML, DG Health Feminine Anti-itchDebrisoquine
go.drugbank.com/drugs/DB04840ApprovedAn adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. … They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesPolatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigational(mc-vc-PAB) that covalently attaches MMAE to polatuzumab. … Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTildrakizumab
go.drugbank.com/drugs/DB14004ApprovedInvestigationalThe approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter [L1858]. … Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis [A32255].
DL-dimyristoylphosphatidylglycerol
go.drugbank.com/drugs/DB11284ApprovedDL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.
Synonyms: DL-dimyristoylphosphatidylglycerolSamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigational, and a longer half-life, making it an attractive candidate for oral dosing. … [A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesVorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigational[A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms. … Vorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates